Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

Groundbreaking chemical technique could reveal new treatments for cancer and other diseases

by Medical Finance
in News
PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Leicester researchers have described application of a pioneering chemical technique which could unlock ground-breaking new treatments for cancer and other diseases.

Members of the Leicester Institute of Structural and Chemical Biology, based at the University of Leicester, used proteolysis targeting chimeras (PROTACs) as a ‘bridge’ to degrade proteins implicated in cancer.

Scientists can manipulate the effectiveness of treatments by making changes to elements of this PROTAC bridge.

This new study, published this week in the Journal of Medicinal Chemistry, describes how Leicester researchers applied a previously-described protein degradation technique known as PROTACs to degrade histone deacetylation enzymes (HDACs) in a more targeted way than ever before.

HDACs play an important role in gene regulation, in which genes are switched ‘on’ and ‘off’, and are associated with a range of diseases, including cancer as well as various neurodegenerative disorders including Alzheimer’s disease.

Using this pioneering technique to target specific structures within cancerous cells could increase the potency and selectivity of new and existing drugs, meaning patients would require lower systemic exposure to drug treatments leading to a reduction in harmful side-effects to patients.

The group have been granted a patent by the European Patent Office for the pioneering technique.

Dr James Hodgkinson is an Associate Professor in Organic Chemistry and Chemical Biology at the University of Leicester and one of the corresponding authors for the study.

We are really excited about what these new molecules are capable of in cancer cells and their potential future development into medicines. Our next steps will involve optimizing their chemical structure and biological properties so that one day they could be used to improve the lives of cancer patients.”


Dr James Hodgkinson, Associate Professor in Organic Chemistry and Chemical Biology, University of Leicester

John Schwabe is Professor of Structural Biology and Director of the Leicester Institute of Structural and Chemical Biology, and also a corresponding author on the study. Professor Schwabe added:

“The potential of using specific degraders of therapeutic targets is very powerful.

“This work has been the result of a productive three-way collaboration between chemists, biologists and biophysicists – an exciting combination to deliver interdisciplinary research.”

The Leicester Institute of Structural and Chemical Biology leads interdisciplinary research across 22 separate research groups at the University of Leicester.

Other work includes innovative research to create a potential vaccine against Alzheimer’s disease.

‘Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells’ is published in the Journal of Medicinal Chemistry.

Leicester Institute of Structural & Chemical Biology – Dr James T Hodgkinson

Video Credit: University of Leicester

Source:

Journal reference:

Smalley, J.P., et al. (2022) Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. Journal of Medicinal Chemistry. doi.org/10.1021/acs.jmedchem.1c02179.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

New and improved method for imaging the structure of neural connections

by Medical Finance
May 20, 2022
0

The glory of tissue expansion technologies is that when structures, such as proteins that build nerve cell connections, are too...

Flowmeter Solutions for High-Speed Batch Dosing

Flowmeter Solutions for High-Speed Batch Dosing

by Medical Finance
May 20, 2022
0

Titan Enterprises has published a white paper reporting on an investigation into the use of electronic flow meters in high-speed...

Macrophages in the arteries can “sniff” out their surroundings and cause inflammation

Macrophages in the arteries can “sniff” out their surroundings and cause inflammation

by Medical Finance
May 20, 2022
0

An artery is not like a nose. Or is it? Scientists at La Jolla Institute for Immunology (LJI) have discovered...

NanoWizard V BioScience AFM

Bruker introduces fast BioAFM for automated mechanobiology

by Medical Finance
May 20, 2022
0

From Bruker JPKJan 12 2022Reviewed by Mychealla Rice Bruker today announced the release of the JPK NanoWizard® V BioAFM, a...

Study: Differential Peripheral Blood Glycoprotein Profiles in Symptomatic and Asymptomatic COVID-19. Image Credit: Corona Borealis Studio/Shutterstock

Mapping peripheral blood glycoprotein profiles of COVID-19 patients

by Medical Finance
May 20, 2022
0

In a recently published study on the medRxiv* pre-print server, a team of researchers analyzed differential protein glyco-isoform distributions of...

UCLA study provides new insights into molecular ‘crosstalk’ in pancreas cancer cells

UCLA study provides new insights into molecular ‘crosstalk’ in pancreas cancer cells

by Medical Finance
May 20, 2022
0

Research led by scientists at the Jonsson Comprehensive Cancer Center (JCCC) at UCLA provides new insights into molecular "crosstalk" in...

Next Post
Nutritional components hold promise for improving the health and well-being of adults

Molecular RNA profile of naked mole-rats reveals new insights on skin aging

Study: Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease. Image Credit: SKK Pix / Shutterstock

Compound found in Datura shows promise as antiviral agent against SARS-CoV-2

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Level and duration of IgG and neutralizing antibodies to SARS-CoV-2 in children with symptomatic or asymptomatic SARS-CoV-2 infection. Image Credit: Kateryna Kon/Shutterstock
    Waning antibody responses in SARS-CoV-2-infected children and adults over time
  • Study: Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?
    How have human organoids been used in research to study SARS-CoV-2?
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply